Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Clinical Trials Innovations

3 abstracts

Abstract
Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.
Org: EpicentRx, Clinical Trials Innovations, Cleveland Clinic Lerner College of Medicine,
Abstract
Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001TGF-ß Trap.
Org: University of Texas MD Anderson Cancer Center, The Cleveland Clinic Foundation, City of Hope National Medical Center, EpicentRx, Mary Crowley Cancer Research Center,
Abstract
KEVLAR: A phase 2b, multi-institutional, randomized, blinded, controlled trial to assess the safety and efficacy of two schedules of RRx-001 vs. standard of care in attenuating severe oral mucositis (SOM) in patients receiving concomitant chemoradiation (CRT) for the treatment of locally advanced squamous cell carcinomas (SCC) of the oral cavity (OC) or oropharynx (OPC).
Org: EpicentRx, La Jolla, CA, Torrey Pines, CA, Clinical Trials Innovations, Mountain View, CA,